Skip to main content
SpringerLink
Log in

Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint

  • Chapter
  • First Online:
Comprehensive Rectal Cancer Care

Abstract

Surgery is the mainstay therapy for rectal cancer. Currently, standard of care includes neoadjuvant and adjuvant treatments for stage II (T3-4, node-negative disease with tumor penetration through the muscle wall) or stage III (node- positive disease without distant metastasis) due to the relatively high risk of locoregional relapse [1]. However, over the past several years, the management algorithm of rectal cancer has become more complex. With the realization that a selected subset of rectal cancers can completely regress after neoadjuvant therapy (NAT), the concept of organ preservation in the context of an apparent clinical complete response has emerged, coupled with the advent of a watch and wait paradigm as well as the concepts of total neoadjuvant therapy (TNT) or treatment intensification programs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network Rectal Cancer (Version 1.2018). https://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf. Accessed 26 Mar 2018.

  2. Monson JRT, Weiser MR, Buie WD, Chang GJ, Rafferty JF, Buie WD, Rafferty J, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56:535–50. https://doi.org/10.1097/DCR.0b013e31828cb66c.

    Article  CAS  PubMed  Google Scholar 

  3. Chen TY-T, Wiltink LM, Nout RA, Meershoek-Klein Kranenbarg E, Laurberg S, Marijnen CAM, van de Velde CJH. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer. 2015;14:106–14. https://doi.org/10.1016/j.clcc.2014.12.007.

    Article  PubMed  Google Scholar 

  4. Ho VP, Lee Y, Stein SL, Temple LKF. Sexual function after treatment for rectal cancer: a review. Dis Colon Rectum. 2011;54:113–25. https://doi.org/10.1007/DCR.0b013e3181fb7b82.

    Article  PubMed  Google Scholar 

  5. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7. discussion 717-718.

    PubMed  PubMed Central  Google Scholar 

  6. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.

    Article  CAS  PubMed  Google Scholar 

  7. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ, Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46. https://doi.org/10.1056/NEJMoa010580.

    Article  CAS  PubMed  Google Scholar 

  8. Bosset J-F, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier J-C, EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23. https://doi.org/10.1056/NEJMoa060829.

    Article  CAS  PubMed  Google Scholar 

  9. Gérard J-P, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M-T, Untereiner M, Leduc B, Francois E, Maurel J, Seitz J-F, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:4620–5. https://doi.org/10.1200/JCO.2006.06.7629.

    Article  Google Scholar 

  10. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens J-H, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40. https://doi.org/10.1056/NEJMoa040694.

    Article  CAS  PubMed  Google Scholar 

  11. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan S-A, McKendrick J, Leong T, Hartopeanu C, Zalcberg J, Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-Tasman radiation oncology group trial 01.04. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3827–33. https://doi.org/10.1200/JCO.2012.42.9597.

    Article  Google Scholar 

  12. Pettersson D, Lörinc E, Holm T, Iversen H, Cedermark B, Glimelius B, Martling A. Tumour regression in the randomized Stockholm III trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102:972–8.; discussion 978. https://doi.org/10.1002/bjs.9811.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Probst CP, Becerra AZ, Aquina CT, Tejani MA, Wexner SD, Garcia-Aguilar J, Remzi FH, Dietz DW, Monson JRT, Fleming FJ, Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh). Extended intervals after neoadjuvant therapy in locally advanced rectal Cancer: the key to improved tumor response and potential organ preservation. J Am Coll Surg. 2015;221:430–40. https://doi.org/10.1016/j.jamcollsurg.2015.04.010.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu C-Y, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770–6. https://doi.org/10.1200/JCO.2011.39.7901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo L-J, Calvo FA, García-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W, Suárez J, Theodoropoulos G, Biondo S, Beets-Tan RGH, Beets GL. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. https://doi.org/10.1016/S1470-2045(10)70172-8.

    Article  PubMed  Google Scholar 

  16. Habr-Gama A, Gama-Rodrigues J, São Julião GP, Proscurshim I, Sabbagh C, Lynn PB, Perez RO. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys. 2014;88:822–8. https://doi.org/10.1016/j.ijrobp.2013.12.012.

    Article  PubMed  Google Scholar 

  17. Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:311–5. https://doi.org/10.1097/DCR.0b013e3182a84eba.

    Article  PubMed  Google Scholar 

  18. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692–8. https://doi.org/10.1007/DCR.0b013e3181f42b89.

    Article  PubMed  Google Scholar 

  19. Garcia-Aguilar J, Shi Q, Thomas CR, Chan E, Cataldo P, Marcet J, Medich D, Pigazzi A, Oommen S, Posner MC. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012;19:384–91. https://doi.org/10.1245/s10434-011-1933-7.

    Article  PubMed  Google Scholar 

  20. Lynn PB, Strombom P, Garcia-Aguilar J. Organ-preserving strategies for the management of near-complete responses in rectal cancer after neoadjuvant chemoradiation. Clin Colon Rectal Surg. 2017;30:395–403. https://doi.org/10.1055/s-0037-1606117.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer Consortium. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767. https://doi.org/10.1186/s12885-015-1632-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99:918–28. https://doi.org/10.1002/bjs.8702.

    Article  CAS  PubMed  Google Scholar 

  23. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg. 2002;194:131–5. discussion 135-136.

    Article  PubMed  Google Scholar 

  24. Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, Paty PB, Saltz L, Minsky BD, Weiser MR, Temple LKF, Cohen AM, Wong WD. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:3475–9. https://doi.org/10.1200/JCO.2005.06.114.

    Article  Google Scholar 

  25. Perez RO, Habr-Gama A, Pereira GV, Lynn PB, Alves PA, Proscurshim I, Rawet V, Gama-Rodrigues J. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis. 2012;14:714–20. https://doi.org/10.1111/j.1463-1318.2011.02761.x.

    Article  CAS  PubMed  Google Scholar 

  26. Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Scanavini Neto A, Gama-Rodrigues J. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum. 2011;54:545–51. https://doi.org/10.1007/DCR.0b013e3182083b84.

    Article  PubMed  Google Scholar 

  27. Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, Brown G. MRI after treatment of locally advanced rectal cancer: how to report tumor response--the MERCURY experience. AJR Am J Roentgenol. 2012;199:W486–95. https://doi.org/10.2214/AJR.11.8210.

    Article  PubMed  Google Scholar 

  28. Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017;18:394. https://doi.org/10.1186/s13063-017-2085-2.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Guillem JG, Ruby JA, Leibold T, Akhurst TJ, Yeung HW, Gollub MJ, Ginsberg MS, Shia J, Suriawinata AA, Riedel ER, Mazumdar M, Saltz LB, Minsky BD, Nash GM, Paty PB, Temple LK, Weiser MR, Larson SM. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study. Ann Surg. 2013;258:289–95. https://doi.org/10.1097/SLA.0b013e318277b625.

    Article  PubMed  Google Scholar 

  30. Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JCR, Lindebjerg J, Rafaelsen SR, Jakobsen A. High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol. 2015;16:919–27. https://doi.org/10.1016/S1470-2045(15)00120-5.

    Article  PubMed  Google Scholar 

  31. Borstlap WAA, van Oostendorp SE, Klaver CEL, Hahnloser D, Cunningham C, Rullier E, Bemelman WA, Tuynman JB, Tanis PJ, Research Committee of the European Society of Coloproctology. (2017) Organ preservation in rectal cancer: a synopsis of current guidelines. Colorectal Dis. https://doi.org/10.1111/codi.13960.

    Article  Google Scholar 

  32. Sammour T, Price BA, Krause KJ, Chang GJ. Nonoperative management or “watch and wait” for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol. 2017;24:1904–15. https://doi.org/10.1245/s10434-017-5841-3.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501–13. https://doi.org/10.1016/S2468-1253(17)30074-2.

    Article  PubMed  Google Scholar 

  34. Araujo RO, Valadao M, Borges D, Linhares E, de Jesus JP, Ferreira CG, Victorino AP, Vieira FM, Albagli R. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015;41(11):1456–63.

    Article  CAS  PubMed  Google Scholar 

  35. Gossedge G, Montazeri A, Nandhra A, Wong H, Artioukh D, Zeiderman M, Chipang A, Myint A. Complete clinical response to chemoradiotherapy for rectal cancer. Is it safe to ‘watch and wait’? Color Dis. 2012;14:20.

    Google Scholar 

  36. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulsewe KW, Buijsen J, Beets GL. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.

    Article  PubMed  Google Scholar 

  37. Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, Temple LK, Nash GM, Paty PB. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012;256:965–72. https://doi.org/10.1097/SLA.0b013e3182759f1c.

    Article  PubMed  Google Scholar 

  38. Lai CL, Lai MJ, Wu CC, Jao SW, Hsiao CW. Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait”. Int J Color Dis. 2016;31(2):413–9.

    Article  Google Scholar 

  39. Li J, Liu H, Yin J, Liu S, Hu J, Du F, Yuan J, Lv B, Fan J, Leng S, Zhang X. Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget. 2015;6:42354–61.

    PubMed  PubMed Central  Google Scholar 

  40. Seshadri RA, Kondaveeti SS, Jayanand SB, John A, Rajendranath R, Arumugam V, Ellusamy HR, Sagar TG. Complete clinical response to neoadjuvant chemoradiation in rectal cancers: can surgery be avoided? Hepatogastroenterology. 2013;60:410–4.

    Google Scholar 

  41. van der Valk MJM, Hilling DE, Bastiaannet E, Kranenbarg EM-K, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH, Ahlberg M, Appelt A, Asoglu O, Bär M-T, Barroca R, Beets-Tan RGH, Belgers EHJ, Bosker RJI, Breukink SO, Bujko K, Carvalho C, Cunningham C, Creavin B, D’Hoore A, Gérard J-P, Gollins S, Hoff C, Holman FA, Hupkens BJP, Iseas S, Jakobsen A, Keshvari A, Koopal SA, Kusters M, Langheinrich M, Leijtens JWA, Maas M, Malcomson L, Mamedli ZZ, Martling A, Matzel KE, Melenhorst J, Morici ML, Murad-Regadas SM, O’Dwyer ST, Peeters KCMJ, Rosa I, Rossi G, Rutten HJT, Loria FS, van der Sande ME, Julião GPS, Saunders M, Myint AS, van der Sluis H, Schiappa R, Scott N, Stoot JHMB, Talsma AK, Terrasson I, Tokmak H, Vaccaro CA, Vahrmeijer AL, Wasowicz DK, Westreenen HL, Winter DC, Wolthuis AM, Zimmerman DDE. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537–45. https://doi.org/10.1016/S0140-6736(18)31078-X.

    Article  PubMed  Google Scholar 

  42. Duldulao MP, Lee W, Streja L, Chu P, Li W, Chen Z, Kim J, Garcia-Aguilar J. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum. 2013;56:142–9. https://doi.org/10.1097/DCR.0b013e31827541e2.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Hupkens BJP, Martens MH, Stoot JH, Berbee M, Melenhorst J, Beets-Tan RG, Beets GL, Breukink SO. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection - a matched-controlled study. Dis Colon Rectum. 2017;60:1032–40. https://doi.org/10.1097/DCR.0000000000000862.

    Article  PubMed  Google Scholar 

  44. Hall MD, Schultheiss TE, Smith DD, Fakih MG, Wong JYC, Chen Y-J. Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol. 2016;55:1392–9. https://doi.org/10.1080/0284186X.2016.1235797.

    Article  CAS  PubMed  Google Scholar 

  45. Appelt AL, Vogelius IR, Pløen J, Rafaelsen SR, Lindebjerg J, Havelund BM, Bentzen SM, Jakobsen A. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys. 2014;90:110–8. https://doi.org/10.1016/j.ijrobp.2014.05.023.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LKF, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:513–8. https://doi.org/10.1200/JCO.2013.51.7904.

    Article  CAS  Google Scholar 

  47. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz R-D, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab H-R, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T, German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979–89. https://doi.org/10.1016/S1470-2045(15)00159-X.

    Article  CAS  PubMed  Google Scholar 

  48. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:2773–80. https://doi.org/10.1200/JCO.2010.34.4911.

    Article  CAS  Google Scholar 

  49. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt SR, Stamos MJ, Ternent CA, Herzig DO, Fichera A, Polite BN, Dietz DW, Patil S, Avila K, Timing of Rectal Cancer Response to Chemoradiation Consortium. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957–66. https://doi.org/10.1016/S1470-2045(15)00004-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nilsson PJ, van Etten B, Hospers GAP, Påhlman L, van de Velde CJH, Beets-Tan RGH, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CAM, Nagtegaal ID, Wiggers T, Glimelius B. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial. BMC Cancer. 2013;13:279. https://doi.org/10.1186/1471-2407-13-279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Martens MH, Maas M, Heijnen LA, Lambregts DMJ, Leijtens JWA, Stassen LPS, Breukink SO, Hoff C, Belgers EJ, Melenhorst J, Jansen R, Buijsen J, Hoofwijk TGM, Beets-Tan RGH, Beets GL. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108:djw171. https://doi.org/10.1093/jnci/djw171.

    Article  PubMed  Google Scholar 

  52. Dijkhoff RAP, Beets-Tan RGH, Lambregts DMJ, Beets GL, Maas M. Value of DCE-MRI for staging and response evaluation in rectal cancer: a systematic review. Eur J Radiol. 2017;95:155–68. https://doi.org/10.1016/j.ejrad.2017.08.009.

    Article  PubMed  Google Scholar 

  53. Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJWL, Dekker A, Fenstermacher D, Goldgof DB, Hall LO, Lambin P, Balagurunathan Y, Gatenby RA, Gillies RJ. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234–48. https://doi.org/10.1016/j.mri.2012.06.010.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Liu Z, Zhang X-Y, Shi Y-J, Wang L, Zhu H-T, Tang Z, Wang S, Li X-T, Tian J, Sun Y-S. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin Cancer Res. 2017;23:7253–62. https://doi.org/10.1158/1078-0432.CCR-17-1038.

    Article  CAS  PubMed  Google Scholar 

  55. Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, Sala E, Garcia-Aguilar J, Gollub MJ, Petkovska I. MR imaging of rectal cancer: radiomics analysis to assess treatment response after neoadjuvant therapy. Radiology. 2018;287:833–43. https://doi.org/10.1148/radiol.2018172300.

    Article  PubMed  Google Scholar 

  56. Koyama FC, Lopes Ramos CM, Ledesma F, Alves VAF, Fernandes JM, Vailati BB, São Julião GP, Habr-Gama A, Gama-Rodrigues J, Perez RO, Camargo AA. Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. Br J Surg. 2018;105:e192–203. https://doi.org/10.1002/bjs.10695.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Felipe Quezada-Díaz & J. Joshua Smith

  2. Colorectal Unit, Royal Adelaide Hospital, University of Adelaide, Adelaide, SA, Australia

    Tarik Sammour

  3. Department of Surgery, Weill Cornell Medical College, New York, NY, USA

    J. Joshua Smith

  4. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Y. Nancy You

Authors
  1. Felipe Quezada-Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarik Sammour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Joshua Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. Nancy You
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Nancy You .

Editor information

Editors and Affiliations

  1. University of California, Los Angeles, Los Angeles, CA, USA

    Mary Kwaan

  2. University of Melbourne, Victoria, VIC, Australia

    Andrew Zbar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Quezada-Díaz, F., Sammour, T., Joshua Smith, J., Nancy You, Y. (2019). Watch and Wait in Rectal Cancer Patients with Clinical Complete Response to Neoadjuvant Therapy: The American Viewpoint. In: Kwaan, M., Zbar, A. (eds) Comprehensive Rectal Cancer Care. Springer, Cham. https://doi.org/10.1007/978-3-319-98902-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98902-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98901-3

  • Online ISBN: 978-3-319-98902-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation